Patent ID: 9133439
Filing Date: 2015-09-15
Classification: C12N

Abstract:
1. A method for increasing the expression of NGN3 and NKX6.1 in a population of pancreatic endoderm cells comprising the steps of: a) obtaining human embryonic stem cells, b) differentiating the human embryonic stem cells into definitive endoderm cells by treating the human embryonic stem cells with a medium supplemented with a TGF-β receptor agonist, c) differentiating the definitive endoderm cells into pancreatic endoderm cells by culturing the definitive endoderm cells in a medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, GW 5074, hydroxy-2-naphthalenylmethylphosphonic acid, AG490, Y27632, and ML-7, and d) differentiating the pancreatic endoderm cells into pancreatic endocrine cells by culturing the pancreatic endoderm cells with noggin, wherein the method increases the expression of NGN3 and NKX6.1 in pancreatic endoderm cells compared to pancreatic endoderm cells differentiated from definitive endoderm cells that are not treated with the compound.